Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 213

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 213
---
 working on a variety of approaches to the treatment of T1D. There are over 400 studies listed as recruiting in T1D
based on the clinicaltrials.gov website.

There are a limited number
of products approved for the treatment of GBM with the current standard of care being surgical resection followed by radiation in combination
with temozolomide. There is no formalized standard of care for the treatment of recurrent GBM or DMG. There are a number of companies
researching potential therapeutic treatments of GBM including CNS Pharmaceuticals, Inc. and Plus Therapeutics, Inc. Chimerix Inc. is among
a number of companies developing a product for DMG. There are approximately 340 studies listed as recruiting in GBM and approximately
70 studies recruiting in DMG based on the clinicaltrials.gov website.

Manufacturing

We do not have our own manufacturing
facilities and we rely on GMP-certified contract manufacturers for our clinical trial material.

Environmental Matters and Seasonality

We may from time to time be
subject to various environmental, health and safety laws and regulations, including those governing air emissions, water and wastewater
discharges, noise emissions, the use, management and disposal of hazardous, radioactive and biological materials and wastes and the cleanup
of contaminated sites. We believe that our business, operations and facilities are being operated in compliance in all material respects
with applicable environmental and health and safety laws and regulations. Based on information currently available to us, we do not expect
environmental costs and contingencies to have a material adverse effect on it. The operation of our laboratory-scale manufacturing facility,
however, entails risks in these areas. Significant expenditures could be required in the future if these facilities are required to comply
with new or more stringent environmental or health and safety laws, regulations or requirements.

Our current business does
not generally reflect any significant degree of seasonality.

Legal Proceedings

From time to time, we may
be subject to various claims or legal proceedings that arise in the ordinary course of our business. Other than as disclosed in this annual
report, we currently are not a party to any legal proceedings, which, in the opinion of management, is likely to have or could reasonably
possibly have a material adverse effect on our business, financial condition or results of operations.

Property, Plant and Equipment

Our current headquarters is
located at 1 Caspian Point, Caspian Way, Cardiff, Wales, where we also have our laboratories and pilot scale manufacturing facility. We